Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9933624 | 0.86 | KMT2A (0.44) | TSHRKDM4EALDH1A1KMT2ALMNA | |
| SCHEMBL9934231 | 0.85 | KMT2A (0.55) | TSHRKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL9934707 | 0.85 | UBE2N (0.43) | KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL9933957 | 0.83 | ALDH1A1 (0.52) | ALDH1A1KMT2AMEN1POLB | |
| SCHEMBL9935464 | 0.83 | MAPT (0.51) | TSHRALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL9933790 | 0.83 | MAPT (0.51) | TSHRALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL9934138 | 0.83 | LMNA (0.44) | TSHRKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL9934664 | 0.83 | MAPT (0.51) | TSHRALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL9933959 | 0.83 | NOTUM (0.42) | KDM4EALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL9934211 | 0.83 | NOTUM (0.42) | KDM4EALDH1A1KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157494-A1 | ISOINDOLYL COMPOUNDS | HARRIS III RALPH NEW (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157494-A1 | ISOINDOLYL COMPOUNDS | HARRIS III RALPH NEW (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157494-A1 | ISOINDOLYL COMPOUNDS | P2RX7, P2RX3, P2RX1 | TSHR 2175/4885KDM4E 4645/4885ALDH1A1 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.